Supplementary Table 1. ConPhyMP-informed reporting summary for multi-component plant-derived interventions and electroacupuncture included in this review.

Intervention	Intervention type	Source or manufacturer	Batch/lot/COA	Preparation or formulation	Chemical profile or fingerprint	Marker quantification	Overall reporting	Notes	References
GRS	Defined 3-compound combination	Partial	NR	NA (defined combination)	NA (not an extract)	NA	Partial	Composition explicitly defined, but no extract-level ConPhyMP profile was required.	[1]
Shenmai Injection	Injection	Reported	NR	Partial	Reported	Reported	Moderate to good	Commercial injectable preparation with reported analytical profiling and marker information, but no explicit batch-level documentation.	[2]

Guanxinning Injection	Injection	Reported	NR	Partial	Partial	NR	Partial	Manufacturer/regulatory source was reported; chemical characterization was limited to major constituents rather than a full batch-level profile.	[3]
Shuangshen Ningxin Formula	Capsule	Partial	NA	Reported	NR	NR	Partial to poor	Formula composition and preparation were described, but explicit chromatographic fingerprinting and marker quantification were not clearly reported.	[4]
Taohong Siwu Decoction	Decoction	Partial	NA	Reported	NR	NR	Partial to poor	Classical formula composition and	[5]

								decoction intervention were described, but no explicit chemical profile was reported.	
QiShenYiQi Dripping Pill	Patent medicine/dripping pill	Reported	NR	NA/Partial	NR	NR	Partial	Commercial multi-component product with defined formula background, but study-level chemical characterization was limited.	[6]
Danqi Soft Capsule	Patent medicine/capsule	Reported	NR	NA/Partial	NR	NR	Partial	Commercial formula was identifiable, but batch-level QC and explicit analytical profiling were not clearly documented.	[7]

Tongmai Yangxin Pill	Patent medicine/pill	Reported	NR	NA/Partial	NR	NR	Partial	Formula composition was available, but explicit batch-level chemical fingerprinting and marker quantification were not clearly reported.	[8]
Electroacupuncture pretreatment	Non-pharmacological intervention	NA	NA	NA	NA	NA	NA	ConPhyMP extract-characterization domains are not applicable to electroacupuncture.	[9]

This table provides a reporting-completeness summary informed by the Consensus statement on Phytochemical Characterisation of Medicinal Plant extracts (ConPhyMP) for the multi-component plant-derived interventions and electroacupuncture included in this review. “Reported” indicates explicit reporting in the source article; “Partial” indicates incomplete reporting; “NR” indicates not reported; and “NA” indicates not applicable. For commercial preparations, batch or lot information and certificates of analysis were recorded only when explicitly reported. For defined combinations of isolated compounds and for electroacupuncture, extract-specific preparation, fingerprinting, and marker-quantification

domains were considered not applicable. The “Overall reporting” column provides a descriptive synthesis of the preceding domains and is not a validated score. Reporting status was determined from the original articles and does not constitute a full ConPhyMP compliance assessment.

Abbreviations: COA, certificate of analysis; GRS, combination of ginsenoside Rb1, ruscogenin, and schisandrin; NA, not applicable; NR, not reported.

Supplementary Table 2. ConPhyMP-informed reporting summary for chemically defined plant-derived compounds included in this review.

Compound	Compound identity	Major plant source annotation	Explicit structural or analytical information	ConPhyMP extract items	Notes	References
Ginsenoside Rg1	Reported	Reported	Partial	NA	Identity was clear; no dedicated chemical analytical profile was explicitly presented.	[10]
Ginsenoside Rg1	Reported	Reported	Partial	NA	Identity and herbal source were clear; the study emphasis was mechanistic rather than analytical.	[11]

Ginsenoside Rg5	Reported	Reported	Partial	NA	Compound identity was defined; no explicit analytical spectrum was central to the reviewed report.	[12]
Ginsenoside Rc	Reported	Reported	Partial	NA	Identity was clear; evidence was mainly mechanistic and metabolic rather than based on direct fusion-fission profiling.	[13]
Calenduloside E	Reported	Reported	Partial	NA	Structural illustration supports identity but does not constitute an extract-type ConPhyMP profile.	[14]
Astragalosidic acid (LS-102)	Reported	Partial	Partial	NA	Semi-synthetic derivative; parent-source annotation can be given, but extract-type fingerprinting is not applicable.	[15]
Notoginsenoside R1	Reported	Reported	Partial	NA	Identity and source were clear; no explicit analytical spectrum was a major focus of the reviewed article.	[16]

Gastrodin	Reported	Reported	Partial	NA	Compound identity was reported; no dedicated chemical analytical profile was clearly presented.	[17]
Salidroside	Reported	Reported	Partial	NA	Identity and source were clear; analytical profiling was not explicitly detailed.	[18]
Vitexin	Reported	Reported	Partial	NA	Compound identity and major source were reported; structural information, where shown, was supportive only.	[19]
Vitexin	Reported	Reported	Partial	NA	Compound identity and source annotation were clear; no dedicated chemical analytical profile was explicitly reported.	[20]
Berberine	Reported	Reported	Partial	NA	Chemical form was identifiable, but no explicit analytical spectrum was central to the reviewed report.	[21]

Rhein	Reported	Reported	Partial	NA	Identity and source were reported; extract-specific ConPhyMP profiling does not apply.	[22]

This table summarizes the reporting of compound identity, major plant source annotation, and explicit structural or analytical information for chemically defined plant-derived compounds included in this review. The "ConPhyMP extract items" column documents whether extract-specific domains from the Consensus statement on Phytochemical Characterisation of Medicinal Plant extracts (ConPhyMP) apply. Because the included interventions are isolated or chemically defined compounds rather than botanical extracts, these domains were considered not applicable (NA) for all entries. "Reported" indicates that the relevant information was explicitly provided in the original study; "Partial" indicates incomplete reporting; "NR" indicates not reported; and "NA" indicates not applicable. This ConPhyMP-informed assessment reflects only the information reported in the original articles and does not constitute a full ConPhyMP compliance assessment or the generation of new analytical data.

REFERENCES

1 **Li F**, Fan X, Zhang Y, Pang L, Ma X, Song M, Kou J, Yu B. Cardioprotection by combination of three compounds from ShengMai preparations in mice with myocardial ischemia/reperfusion injury through AMPK activation-mediated mitochondrial fission. *Sci Rep* 2016; **6**: 37114 [PMID: 27869201 DOI: 10.1038/srep37114]

2 **Yu J**, Li Y, Liu X, Ma Z, Michael S, Orgah JO, Fan G, Zhu Y. Mitochondrial dynamics modulation as a critical contribution for Shenmai injection in attenuating hypoxia/reoxygenation injury. *J Ethnopharmacol* 2019; **237**: 9-19 [PMID: 30880258 DOI: 10.1016/j.jep.2019.03.033]

3 **Wang A**, Zhang D, Liu J, Yan H, Zhang P, Yuan H, Ma X. Guanxinning Injection Combined With Ischemic Postconditioning Attenuate Myocardial Ischemic Reperfusion Injury in Chronic Renal Failure Rats by Modulating Mitochondrial Dynamics. *Front Cardiovasc Med* 2022; **9**: 905254 [PMID: 35711377 DOI: 10.3389/fcvm.2022.905254]

4 **Liu Z**, Han X, You Y, Xin G, Li L, Gao J, Meng H, Cao C, Liu J, Zhang Y, Li L, Fu J. Shuangshen ningxin formula attenuates cardiac microvascular ischemia/reperfusion injury through improving mitochondrial function. *J Ethnopharmacol* 2024; **323**: 117690 [PMID: 38195019 DOI: 10.1016/j.jep.2023.117690]

5 **Luo ZR**, Li H, Xiao ZX, Shao SJ, Zhao TT, Zhao Y, Mou FF, Yu B, Guo HD. Taohong Siwu Decoction Exerts a Beneficial Effect on Cardiac Function by Possibly Improving the Microenvironment and Decreasing Mitochondrial Fission after Myocardial Infarction. *Cardiol Res Pract* 2019; **2019**: 5198278 [PMID: 31885903 DOI: 10.1155/2019/5198278]

6 **Wu L**, Fan Z, Gu L, Liu J, Cui Z, Yu B, Kou J, Li F. QiShenYiQi dripping pill alleviates myocardial ischemia-induced ferroptosis via improving mitochondrial dynamical homeostasis and biogenesis. *J Ethnopharmacol* 2023; **308**: 116282 [PMID: 36806343 DOI: 10.1016/j.jep.2023.116282]

7 **Yang Y**, Lin C, Wang Y, Liu Y, Chen Q, Ma S, Ma J. Danqi soft caspule alleviates myocardial ischemia-reperfusion injury induced cardiomyocyte apoptosis by attenuating mitochondrial fission. *Front Pharmacol* 2025; **16**: 1526253 [PMID: 40144667 DOI: 10.3389/fphar.2025.1526253]

8 **Yu L**, Wang X, Lei Q, Liu Y, Li Z, Dai X, Song Z, He Y, Gao S, Yu C, Li L. Tongmai Yangxin pill alleviates myocardial ischemia/reperfusion injury by regulating mitochondrial fusion and fission through the estrogen receptor alpha/peroxisome proliferator-activated receptor gamma coactivator-1 alpha signaling pathway. *J Ethnopharmacol* 2025; **345**: 119639 [PMID: 40096900 DOI: 10.1016/j.jep.2025.119639]

9 **Zhang Y**, Wu S, Guo Q, Yu Y, Wang S, Wei Y, Wan X, Lu Z, He X. [Mechanism of the pretreatment with electroacupuncture of "biaoben acupoint combination" for regulating cardiomyocyte mitochondrial fission in the rats of myocardial ischemia-reperfusion injury]. *Zhongguo Zhen Jiu* 2025; **45**: 335-344 [PMID: 40097217 DOI: 10.13703/j.0255-2930.20240317-k0004]

10 **Dong G**, Chen T, Ren X, Zhang Z, Huang W, Liu L, Luo P, Zhou H. Rg1 prevents myocardial hypoxia/reoxygenation injury by regulating mitochondrial dynamics imbalance via modulation of glutamate dehydrogenase and mitofusin 2. *Mitochondrion* 2016; **26**: 7-18 [PMID: 26593335 DOI: 10.1016/j.mito.2015.11.003]

11 **Zhang HY**, Cui XS, Chen YY, Xin GJ, Cao C, Liu ZX, Xu SJ, Gao JM, Guo H, Fu JH. [Alleviation of hypoxia/reoxygenation injury in HL-1 cells by ginsenoside Rg_1 via regulating mitochondrial fusion based on Notch1 signaling pathway]. *Zhongguo Zhong Yao Za Zhi* 2025; **50**: 2711-2718 [PMID: 40686140 DOI: 10.19540/j.cnki.cjcmm.20241219.403]

12 **Yang YL**, Li J, Liu K, Zhang L, Liu Q, Liu B, Qi LW. Ginsenoside Rg5 increases cardiomyocyte resistance to ischemic injury through regulation of mitochondrial hexokinase-II and dynamin-related protein 1. *Cell Death Dis* 2017; **8**: e2625 [PMID: 28230856 DOI: 10.1038/cddis.2017.43]

13 **Huang Q**, Su H, Qi B, Wang Y, Yan K, Wang X, Li X, Zhao D. A SIRT1 Activator, Ginsenoside Rc, Promotes Energy Metabolism in Cardiomyocytes and Neurons. *J Am Chem Soc* 2021; **143**: 1416-1427 [PMID: 33439015 DOI: 10.1021/jacs.0c10836]

14 **Wang M**, Wang RY, Zhou JH, Xie XH, Sun GB, Sun XB. Calenduloside E Ameliorates Myocardial Ischemia-Reperfusion Injury through Regulation of AMPK and Mitochondrial OPA1. *Oxid Med Cell Longev* 2020; **2020**: 2415269 [PMID: 32934760 DOI: 10.1155/2020/2415269]

15 **Chen L**, Chen XY, Wang QL, Yang SJ, Zhou H, Ding LS, Qing LS, Luo P. Astragaloside IV Derivative (LS-102) Alleviated Myocardial Ischemia Reperfusion Injury by Inhibiting Drp1(Ser616) Phosphorylation-Mediated Mitochondrial Fission. *Front Pharmacol* 2020; **11**: 1083 [PMID: 33041784 DOI: 10.3389/fphar.2020.01083]

16 **Xu Y**, Wang P, Hu T, Ning K, Bao Y. Notoginsenoside R1 Attenuates H/R Injury in H9c2 Cells by Maintaining Mitochondrial Homeostasis. *Curr Issues Mol Biol* 2025; **47**: 44 [PMID: 39852159 DOI: 10.3390/cimb47010044]

17 **Cheng QQ**, Wan YW, Yang WM, Tian MH, Wang YC, He HY, Zhang WD, Liu X. Gastrodin protects H9c2 cardiomyocytes against oxidative injury by ameliorating imbalanced mitochondrial dynamics and mitochondrial dysfunction. *Acta Pharmacol Sin* 2020; **41**: 1314-1327 [PMID: 32203078 DOI: 10.1038/s41401-020-0382-x]

18 **Tian X**, Huang Y, Zhang X, Fang R, Feng Y, Zhang W, Li L, Li T. Salidroside attenuates myocardial ischemia/reperfusion injury via AMPK-induced suppression of endoplasmic reticulum stress and mitochondrial fission. *Toxicol Appl Pharmacol* 2022; **448**: 116093 [PMID: 35659894 DOI: 10.1016/j.taap.2022.116093]

19 **Xue W**, Wang X, Tang H, Sun F, Zhu H, Huang D, Dong L. Vitexin attenuates myocardial ischemia/reperfusion injury in rats by regulating mitochondrial dysfunction induced by mitochondrial dynamics imbalance. *Biomed Pharmacother* 2020; **124**: 109849 [PMID: 31972356 DOI: 10.1016/j.biopha.2020.109849]

20 **Yang H**, Xue W, Ding C, Wang C, Xu B, Chen S, Zha B, Sun Y, Zhu H, Zhang J, Dong L. Vitexin Mitigates Myocardial Ischemia/Reperfusion Injury in Rats by Regulating Mitochondrial Dysfunction via Epac1-Rap1 Signaling. *Oxid Med Cell Longev* 2021; **2021**: 9921982 [PMID: 34257823 DOI: 10.1155/2021/9921982]

21 **Yang Y**, Jiang S, Mu Y, Liu C, Han Y, Jiang J, Wang Y. Berberine prevents against myocardial injury induced by acute β-adrenergic overactivation in rats. *J Appl Toxicol* 2024; **44**: 1700-1713 [PMID: 38981847 DOI: 10.1002/jat.4659]

22 **Li H**, Jia Y, Yao D, Gao M, Wang L, Liu J. Rhein alleviates myocardial ischemic injury by inhibiting mitochondrial division, activating mitochondrial autophagy and suppressing myocardial cell apoptosis through the Drp1/Pink1/Parkin pathway. *Mol Biol Rep* 2024; **51**: 266 [PMID: 38302764 DOI: 10.1007/s11033-023-09154-1]